AU2016349701B2 - Enrich and amplify highly potent human mesenchymal stem cells from elderly cell populations - Google Patents

Enrich and amplify highly potent human mesenchymal stem cells from elderly cell populations Download PDF

Info

Publication number
AU2016349701B2
AU2016349701B2 AU2016349701A AU2016349701A AU2016349701B2 AU 2016349701 B2 AU2016349701 B2 AU 2016349701B2 AU 2016349701 A AU2016349701 A AU 2016349701A AU 2016349701 A AU2016349701 A AU 2016349701A AU 2016349701 B2 AU2016349701 B2 AU 2016349701B2
Authority
AU
Australia
Prior art keywords
mscs
cells
small
young
donor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2016349701A
Other languages
English (en)
Other versions
AU2016349701A1 (en
Inventor
Travis Block
Xiao-Dong Chen
Milos MARINKOVIC
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
The University of Texas System
Original Assignee
The University of Texas System
The University of Texas at Austin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The University of Texas System, The University of Texas at Austin filed Critical The University of Texas System
Publication of AU2016349701A1 publication Critical patent/AU2016349701A1/en
Application granted granted Critical
Publication of AU2016349701B2 publication Critical patent/AU2016349701B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/90—Substrates of biological origin, e.g. extracellular matrix, decellularised tissue

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
AU2016349701A 2015-11-04 2016-11-04 Enrich and amplify highly potent human mesenchymal stem cells from elderly cell populations Ceased AU2016349701B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562250664P 2015-11-04 2015-11-04
US62/250,664 2015-11-04
PCT/US2016/060624 WO2017079621A1 (en) 2015-11-04 2016-11-04 Enrich and amplify highly potent human mesenchymal stem cells from elderly cell populations

Publications (2)

Publication Number Publication Date
AU2016349701A1 AU2016349701A1 (en) 2018-05-24
AU2016349701B2 true AU2016349701B2 (en) 2023-10-19

Family

ID=58662777

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016349701A Ceased AU2016349701B2 (en) 2015-11-04 2016-11-04 Enrich and amplify highly potent human mesenchymal stem cells from elderly cell populations

Country Status (8)

Country Link
US (1) US11802272B2 (enExample)
EP (1) EP3370740A4 (enExample)
JP (2) JP6871637B2 (enExample)
CN (1) CN108601799A (enExample)
AU (1) AU2016349701B2 (enExample)
CA (1) CA3004296A1 (enExample)
HK (1) HK1254739A1 (enExample)
WO (1) WO2017079621A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190153386A1 (en) * 2017-11-17 2019-05-23 James R. Musick Stem cell line for treatment of various medical conditions
CN113166722A (zh) 2018-10-03 2021-07-23 斯特姆生物系统有限公司 羊水细胞来源的细胞外基质及其用途
CN113728092B (zh) 2019-02-21 2025-04-22 斯特姆生物系统有限公司 心肌细胞在羊水细胞来源的ecm上成熟化的方法、细胞构建体及用于药物化合物的心脏毒性和致心律失常筛查的用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7807458B2 (en) * 2003-01-30 2010-10-05 The United States Of America As Represented By The Secretary Of The Department Of Veterans Affairs Multilineage-inducible cells and uses thereof
US9155762B2 (en) * 2005-12-08 2015-10-13 University Of Louisville Research Foundation, Inc. Uses and isolation of stem cells from bone marrow
CN101573441A (zh) * 2005-12-08 2009-11-04 路易斯维尔大学研究基金会有限公司 非常小的胚胎样（vsel）干细胞及分离和利用其的方法
US8084023B2 (en) 2007-01-22 2011-12-27 The Board Of Trustees Of The University Of Arkansas Maintenance and propagation of mesenchymal stem cells
CN102333861A (zh) * 2008-09-30 2012-01-25 路易斯维尔大学研究基金会有限公司 用于分离非常小的胚胎样(vsel)干细胞的方法
KR20120003470A (ko) 2009-03-31 2012-01-10 더 보드 오브 리전츠 오브 더 유니버시티 오브 텍사스 시스템 사람 제대혈 유래의 중간엽 줄기 세포의 분리
AU2011299327B2 (en) 2010-09-07 2015-07-16 The Board Of Regents Of The University Of Texas System Tissue-specific differentiation matrices and uses thereof
EP2694651A4 (en) 2011-04-01 2014-11-26 Univ Louisville Res Found METHOD AND COMPOSITIONS FOR THE LARGE INSULATION OF VERY SMALL EMBRYONAL-SIMILAR STEM CELLS
PL2785359T3 (pl) * 2011-11-30 2018-12-31 Astellas Institute For Regenerative Medicine Mezenchymalne komórki zrębowe i związane z nimi zastosowania
US20170335286A1 (en) 2014-10-30 2017-11-23 Stembiosys, Inc. Methods for maintaining and expanding mesenchymal stem cells on extracellular matrix coated microcarriers

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Hall, S.R.R. et al., Stem Cells Translational Medicine. 2013, Vol. 2, No. 8, pages 567-578 *
Igura, K. et al., AMERICAN JOURNAL OF PHYSIOLOGY - HEART AND CIRCULATORY PHYSIOLOGY. 2013, Vol. 305, No. 9, pages H1354-H1362 *

Also Published As

Publication number Publication date
US11802272B2 (en) 2023-10-31
CA3004296A1 (en) 2017-05-11
JP6871637B2 (ja) 2021-05-12
EP3370740A4 (en) 2019-05-22
JP2021105047A (ja) 2021-07-26
US20180320140A1 (en) 2018-11-08
EP3370740A1 (en) 2018-09-12
WO2017079621A1 (en) 2017-05-11
HK1254739A1 (zh) 2019-07-26
AU2016349701A1 (en) 2018-05-24
JP7153951B2 (ja) 2022-10-17
JP2018537440A (ja) 2018-12-20
CN108601799A (zh) 2018-09-28

Similar Documents

Publication Publication Date Title
Kornicka et al. The effect of age on osteogenic and adipogenic differentiation potential of human adipose derived stromal stem cells (hASCs) and the impact of stress factors in the course of the differentiation process
Hua et al. Comparison of different methods for the isolation of mesenchymal stem cells from umbilical cord matrix: proliferation and multilineage differentiation as compared to mesenchymal stem cells from umbilical cord blood and bone marrow
KR101507172B1 (ko) 동결된 제대조직으로부터 유래하는 생존가능한 세포
US20220184136A1 (en) Highly functional manufactured abcb5+ mesenchymal stem cells
Bernacki et al. Isolation of human mesenchymal stem cells from bone and adipose tissue
KR20080063406A (ko) 태반 줄기세포를 이용한 면역 조절
JP7153951B2 (ja) 高齢細胞集団由来の高い分化能を有するヒト間葉系幹細胞の濃縮および増幅
US20200270579A1 (en) Method for preparing dental pulp stem cells from cells derived from dental pulp tissue
DK2723850T3 (en) A method for culturing cells in the platelet lysate-containing medium
Alexander et al. Stromal cells cultivated from the choroid of human eyes display a mesenchymal stromal cell (MSC) phenotype and inhibit the proliferation of choroidal vascular endothelial cells in vitro
De Luca et al. Comparative analysis of mesenchymal stromal cells biological properties
Emnett et al. Evaluation of tissue homogenization to support the generation of GMP‐compliant mesenchymal stromal cells from the umbilical cord
US12391924B2 (en) Method for mesenchymal stem cell isolation and osteoblast differentiation
Labusca et al. Isolation and phenotypic characterisation of stem cells from late stage osteoarthritic mesenchymal tissues
Dabaghi et al. Allografts for partial meniscus repair: an in vitro and ex vivo meniscus culture study
US12441984B2 (en) Isolation, preservation, and expansion of canine umbilical cord mesenchymal stromal cells
Ahmad et al. Human umbilical cord blood serum, a better alternative of fetal bovine serum
Caprio et al. The Effect of Replacing Fetal Bovine Serum with Platelet Releasate on the Characterization of MSCs
Dittmer Decellularized Precision Cut Lung Slices as a model to study in vitro lung regeneration
Shuvalova et al. Proliferation of Wharton jelly mesenchymal stem cells, derived by preserving the cells with reduced attachment rate, under various gas conditions
Kim et al. Isolation and identification of mesenchymal stem cells from human mastoid bone marrow
Sheard Screening and improving the safe provision of mesenchymal stem cells in regenerative medicine: an in vitro study
Kornicka et al. Research Article The Effect of Age on Osteogenic and Adipogenic Differentiation Potential of Human Adipose Derived Stromal Stem Cells (hASCs) and the Impact of Stress Factors in the Course of the Differentiation Process
De Luca et al. Research Article Comparative Analysis of Mesenchymal Stromal Cells Biological Properties
Verardi et al. Comparative Analysis of Mesenchymal Stromal Cells Biological Properties

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired